A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder

Schizophrenia Research

Volumn 138, Issue 1, 2012, Pages 35-38

  Weiser, Mark ^a,b   Gershon, Ari A ^a   Rubinstein, Katya ^a   Petcu, Camelia ^c   Ladea, Maria ^c   Sima, Dorina ^c   Podea, Delia ^d   Keefe, Richard S E ^e   Davis, John M ^f  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Spitalul Clinic de Psihiatrie Obregia   (Romania)

^d Clinica de Psihiatrie   (Romania)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Adenosine; Allopurinol; Cognitive; Schizoaffective; Schizophrenia

Indexed keywords

ALLOPURINOL; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTICENTER STUDY; PLACEBO EFFECT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADENOSINE; ADULT; ALLOPURINOL; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME; XANTHINE OXIDASE;

EID: 84861531595     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.02.014     Document Type: Article

References (26)

1. Abbasi S.H., Behpournia H., Ghoreshi A., Salehi B., Raznahan M., Rezazadeh S.A., Rezaei F., Akhondzadeh S. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr. Res. 2009, 116(2-3):101-106.
2. Akhondzadeh S., Safarcherati A., Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29(2):253-259.
3. Atkins M., Burgess A., C.B, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatrist 1997, 21:224-226.
4. Browne R.G., Welch W.M. Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. Science 1982, 217(4565):1157-1159.
5. Brunstein M.G., Ghisolfi E.S., Ramos F.L., Lara D.R. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J. Clin. Psychiatry 2005, 66(2):213-219.
6. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164(10):1593-1602.
7. Chen Y.F., Wang S.J., Khin N.A., Hung H.M., Laughren T.P. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm. Stat. 2010, 9(3):217-229.
8. Delaney S.M., Shepel P.N., Geiger J.D. Levels of endogenous adenosine in rat striatum. I. Regulation by ionotropic glutamate receptors, nitric oxide and free radicals. J. Pharmacol. Exp. Ther. 1998, 285(2):561-567.
9. Dickerson F.B., Stallings C.R., Origoni A.E., Sullens A., Khushalani S., Sandson N., Yolken R.H. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr. Res. 2009, 109(1-3):66-69.
10. Ferre S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 1997, 133(2):107-120.
11. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64(10):1115-1122.
12. Guy W. CGI: Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology 1976, 217-222. National Institute of Mental Health. W. Guy, R.R. Bonato (Eds.).
13. Javitt D.C. Glutamatergic theories of schizophrenia. Isr. J. Psychiatry Relat. Sci. 2010, 47(1):4-16.
14. Kafka S.H., Corbett R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur. J. Pharmacol. 1996, 295(2-3):147-154.
15. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
16. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004, 68(2-3):283-297.
17. Keefe R.S., Harvey P.D., Goldberg T.E., Gold J.M., Walker T.M., Kennel C., Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr. Res. 2008, 102(1-3):108-115.
18. Keefe R.S., Malhotra A.K., Meltzer H.Y., Kane J.M., Buchanan R.W., Murthy A., Sovel M., Li C., Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008, 33(6):1217-1228.
19. Kemp A.S., Schooler N.R., Kalali A.H., Alphs L., Anand R., Awad G., Davidson M., Dube S., Ereshefsky L., Gharabawi G., Leon A.C., Lepine J.P., Potkin S.G., Vermeulen A. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophr. Bull. 2010, 36(3):504-509.
20. Kroken R.A., Johnsen E., Ruud T., Wentzel-Larsen T., Jorgensen H.A. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009, 9:24.
21. Lara D.R., Dall'Igna O.P., Ghisolfi E.S., Brunstein M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(4):617-629.
22. Machado-Vieira R., Soares J.C., Lara D.R., Luckenbaugh D.A., Busnello J.V., Marca G., Cunha A., Souza D.O., Zarate C.A., Kapczinski F. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J. Clin. Psychiatry 2008, 69(8):1237-1245.
23. Marro P.J., Mishra O.P., Delivoria-Papadopoulos M. Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res. 2006, 1073-1074:444-450.
24. Popoli P., Reggio R., Pezzola A. Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats. Eur. J. Pharmacol. 1997, 333(2-3):143-146.
25. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
26. Weiser M., Davidson M., Heresco-Levy U., Abramovich Y., Konas S., Teitelbaum A., Doron A., Liba D., Amital D., Levkovitz Y., Zimmerman Y., Asher R., Gigi K., Gershon A.A., Javitt D.C. A multicenter. Add-On Trial of d-Serine for Negative and Cognitive Symptoms of Schizophrenia 2010.